Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Regulation01:25

Drug Regulation

3.0K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
3.0K
Pharmacovigilance01:19

Pharmacovigilance

2.0K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
2.0K
Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

1.5K
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
1.5K
Upper Respiratory Drugs: First and Second-Generation Antihistamines01:15

Upper Respiratory Drugs: First and Second-Generation Antihistamines

1.8K
Antihistamines are a class of drugs widely used to alleviate the symptoms of allergies, such as sneezing, itching, and nasal congestion. They work by inhibiting the actions of histamine, which is released by immune cells in response to allergenic substances or tissue injuries.
Histamine binds to specific receptor sites, known as H1 receptors, on tissue cells, triggering inflammation and swelling. Antihistamines combat these effects by competing with histamine for these receptor sites. By...
1.8K
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

343
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
343
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

97
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Icotrokinra: First Approval.

Drugs·2026
Same author

Ferric Maltol: Pediatric First Approval.

Paediatric drugs·2026
Same author

Sevabertinib: First Approval.

Drugs·2026
Same author

Retlirafusp Alfa: First Approval.

Drugs·2026
Same author

Zeprumetostat: First Approval.

Drugs·2025
Same author

Brensocatib: First Approval.

Drugs·2025
Same journal

GLP-1 Receptor Agonists and Cardiovascular Outcomes in Patients with Type 2 Diabetes Across Myocardial Infarction-Defined Populations: A Systematic Review and Meta-Analysis.

American journal of cardiovascular drugs : drugs, devices, and other interventions·2026
Same journal

Clinical Pharmacology of Plozasiran.

American journal of cardiovascular drugs : drugs, devices, and other interventions·2026
Same journal

De-risking Atrial Fibrillation: Refining Anticoagulation Decision-Making.

American journal of cardiovascular drugs : drugs, devices, and other interventions·2026
Same journal

Correction: Impact of Aspirin on Primary Prevention of Cardiovascular Events in Patients with Elevated Lipoprotein(a): A Systematic Review and Meta-analysis.

American journal of cardiovascular drugs : drugs, devices, and other interventions·2026
Same journal

Comment on "Polypill Strategy: A Paradigm Shift in Cardiovascular Disease Prevention".

American journal of cardiovascular drugs : drugs, devices, and other interventions·2026
Same journal

Spironolactone or Finerenone for Cardiovascular and Kidney Protection in Patients with Moderate CKD?

American journal of cardiovascular drugs : drugs, devices, and other interventions·2026
See all related articles

Related Experiment Video

Updated: May 5, 2026

Automated Radiochemical Synthesis of [18F]3F4AP: A Novel PET Tracer for Imaging Demyelinating Diseases
11:03

Automated Radiochemical Synthesis of [18F]3F4AP: A Novel PET Tracer for Imaging Demyelinating Diseases

Published on: May 29, 2017

9.9K

Flurpiridaz F 18: First Approval.

Susan J Keam1

  • 1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. cvd@adis.com.

American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|January 25, 2025
PubMed
Summary
This summary is machine-generated.

Flurpiridaz F 18 (FLYRCADO™) is a new PET imaging drug approved for detecting coronary artery disease. It helps evaluate myocardial ischemia and infarction in adults with known or suspected CAD.

More Related Videos

18F-Labeling of Radiotracers Functionalized with a Silicon Fluoride Acceptor SiFA for Positron Emission Tomography
09:57

18F-Labeling of Radiotracers Functionalized with a Silicon Fluoride Acceptor SiFA for Positron Emission Tomography

Published on: January 11, 2020

7.3K
An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use
10:33

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use

Published on: May 24, 2024

697

Related Experiment Videos

Last Updated: May 5, 2026

Automated Radiochemical Synthesis of [18F]3F4AP: A Novel PET Tracer for Imaging Demyelinating Diseases
11:03

Automated Radiochemical Synthesis of [18F]3F4AP: A Novel PET Tracer for Imaging Demyelinating Diseases

Published on: May 29, 2017

9.9K
18F-Labeling of Radiotracers Functionalized with a Silicon Fluoride Acceptor SiFA for Positron Emission Tomography
09:57

18F-Labeling of Radiotracers Functionalized with a Silicon Fluoride Acceptor SiFA for Positron Emission Tomography

Published on: January 11, 2020

7.3K
An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use
10:33

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use

Published on: May 24, 2024

697

Area of Science:

  • Nuclear medicine
  • Cardiovascular imaging
  • Radiopharmaceuticals

Background:

  • Coronary artery disease (CAD) is a leading cause of mortality worldwide.
  • Accurate detection of myocardial ischemia and infarction is crucial for patient management.
  • Positron Emission Tomography (PET) offers high-resolution imaging for cardiovascular assessment.

Purpose of the Study:

  • To summarize the development milestones of Flurpiridaz F 18 (FLYRCADO™).
  • To highlight the recent US FDA approval for PET myocardial perfusion imaging (MPI).
  • To detail its use in evaluating myocardial ischemia and infarction in adult patients.

Main Methods:

  • Flurpiridaz F 18 is an intravenous radioactive diagnostic drug.
  • It is utilized in PET MPI under rest or stress conditions.
  • Development involved clinical trials to establish safety and efficacy.

Main Results:

  • Flurpiridaz F 18 received US FDA approval in September 2024.
  • The drug is indicated for PET MPI in adult patients with known or suspected CAD.
  • It aids in evaluating myocardial ischemia and infarction.

Conclusions:

  • Flurpiridaz F 18 represents a significant advancement in PET MPI for CAD detection.
  • Its approval provides a new diagnostic tool for assessing myocardial health.
  • This development facilitates earlier and more accurate diagnosis of ischemic heart disease.